John Petrie, MD, PhD
Professor of Diabetic Medicine
University of Glasgow
Honorary Consultant Physician and Diabetologist
Glasgow Royal Infirmary and Stobhill Hospital
Glasgow, Scotland
In your mind, what are the most impressive results reported for both primary and secondary end points in the LEADER trial?
By what mechanisms do you think the GLP-1 RA liraglutide might have affected cardiovascular events, based on the finding of the LEADER trial?
Based on LEADER, what does the typical patient with T2D look like who could possibly benefit from CV risk reduction associated with GLP-1 RA therapy? What doses of liraglutide would appear to be optimal?
What did we learn about hypoglycemic risk from the LEADER trial as it relates to the GLP-1 RA evaluated?
What is your assessment of the results of the secondary end points — especially renal markers such as albuminuria — reported in LEADER that may be drivers of atheroinflammatory CV disease? What about the absence of a cancer signal?